Neurofascin — Biomarker for Axonal Integrity
Overview
| Attribute | Value |
|-----------|-------|
| Category | Axonal Integrity Biomarker |
| Target | Neurofascin (NFASC) |
| Sample Type | CSF, Blood |
| Diseases | ALS, MS, PD, AD |
| Sensitivity | High |
| Specificity | Moderate |
Neurofascin is a neuronal cell adhesion molecule that plays a critical role in maintaining axonal integrity and saltatory conduction in myelinated neurons. It exists in multiple isoforms (NFASC155 and NFASC186) with distinct functions at the paranode and axonal initial segment (AIS). As a biomarker, neurofascin provides valuable insights into axonal damage across various neurodegenerative and demyelinating diseases[@howell2015][@santor2018].
Molecular Background
Neurofascin belongs to the L1 family of immunoglobulin superfamily cell adhesion molecules (L1-CAM). The protein contains six Ig-like domains, multiple fibronectin type III repeats, and a cytoplasmic tail that interacts with the cytoskeleton through ankyrin binding[@zhang2020]. This molecular architecture enables neurofascin to form critical stabilizing complexes at key axonal domains.
- NFASC155: Major isoform at the paranode, forms critical complexes with contactin-1 and caspr to maintain the paranodal junction
- NFASC186: Predominant at the axonal initial segment (AIS), partners with ankyrin-G to establish the AIS scaffold
Structural Domains
...Neurofascin — Biomarker for Axonal Integrity
Overview
| Attribute | Value |
|-----------|-------|
| Category | Axonal Integrity Biomarker |
| Target | Neurofascin (NFASC) |
| Sample Type | CSF, Blood |
| Diseases | ALS, MS, PD, AD |
| Sensitivity | High |
| Specificity | Moderate |
Neurofascin is a neuronal cell adhesion molecule that plays a critical role in maintaining axonal integrity and saltatory conduction in myelinated neurons. It exists in multiple isoforms (NFASC155 and NFASC186) with distinct functions at the paranode and axonal initial segment (AIS). As a biomarker, neurofascin provides valuable insights into axonal damage across various neurodegenerative and demyelinating diseases[@howell2015][@santor2018].
Molecular Background
Neurofascin belongs to the L1 family of immunoglobulin superfamily cell adhesion molecules (L1-CAM). The protein contains six Ig-like domains, multiple fibronectin type III repeats, and a cytoplasmic tail that interacts with the cytoskeleton through ankyrin binding[@zhang2020]. This molecular architecture enables neurofascin to form critical stabilizing complexes at key axonal domains.
- NFASC155: Major isoform at the paranode, forms critical complexes with contactin-1 and caspr to maintain the paranodal junction
- NFASC186: Predominant at the axonal initial segment (AIS), partners with ankyrin-G to establish the AIS scaffold
Structural Domains
| Domain | Function |
|--------|----------|
| Ig-like domains (6x) | Cell adhesion, heterophilic interactions |
| Fibronectin III repeats (5x) | Molecular scaffolding |
| Cytoplasmic tail | Ankyrin binding, cytoskeletal linkage |
| FGG motifs | Heparan sulfate attachment |
Biomarker Applications
Axonal Degeneration Marker
Neurofascin is released into cerebrospinal fluid (CSF) and blood during axonal damage. Elevated levels correlate with disease severity and progression across multiple conditions[@devaux2019][@comi2021]:
- ALS disease progression: Higher NFASC levels associated with faster disease progression; studies show correlation with neurofilament light chain (NfL) levels
- Multiple sclerosis: CSF NFASC155 reflects demyelination and axonal loss; useful for monitoring disease activity
- Parkinson's disease: Altered expression patterns in early-stage PD; potential early biomarker
- Alzheimer's disease: Correlates with white matter integrity loss on [MRI](/diagnostics/magnetic-resonance-imaging)
Disease-Specific Mechanisms
Amyotrophic Lateral Sclerosis (ALS)
In ALS, neurofascin release reflects corticospinal tract degeneration. The biomarker correlates with:
- Disease progression rate
- Neurofilament levels
- Motor function decline
- Survival time[@fitzgerald2022]
Multiple Sclerosis (MS)
Neurofascin in MS serves as a marker of:
- Active demyelination
- Axonal transection
- Lesion load on [MRI](/diagnostics/magnetic-resonance-imaging)
- Treatment response[@raj2023]
Parkinson's Disease (PD)
In PD, neurofascin dynamics reflect:
- Nigrostriatal pathway degeneration
- Disease staging
- Levodopa response correlation
- Progression markers[@stathakis2024]
Alzheimer's Disease (AD)
Neurofascin as AD biomarker indicates:
- White matter integrity
- Neurofibrillary tangle burden correlation
- Cognitive decline correlation
- Tau pathology progression[@brown2024]
Diagnostic Utility
| Disease | Utility | Evidence Level | Key Studies |
|---------|---------|----------------|--------------|
| ALS | Prognostic | Moderate | Santor FM 2018, Raj T 2023 |
| MS | Disease activity | High | Howell OW 2015, Comi G 2021 |
| PD | Early detection | Low-Moderate | Zhang Y 2020 |
| AD | Disease progression | Low-Moderate | Fitzgerald KC 2022 |
Detection Methods
| Method | Sensitivity | Sample | Turnaround |
|--------|-------------|--------|-------------|
| ELISA | pg/mL | CSF, Serum | 24-48h |
| Simoa | fg/mL | Plasma | 4-6h |
| Western Blot | Qualitative | CSF | 48-72h |
| Mass Spectrometry | High specificity | CSF | 1-2 weeks |
Sample Handling
- CSF collection: Lumbar puncture, stored at -80°C
- Blood collection: Serum or plasma, centrifuged within 2 hours
- Stability: Stable for 3 months at -80°C, avoid repeated freeze-thaw
- Preanalytical factors: Diurnal variation minimal, fasting not required
Clinical Interpretation
Interpretation Guidelines
- Elevated CSF/serum neurofascin indicates active axonal damage
- Longitudinal tracking useful for monitoring disease progression
- Combined with other axonal markers (NfL), tau) improves diagnostic accuracy
- Isoform-specific analysis (NFASC155 vs NFASC186) provides mechanistic insight
Reference Ranges
| Condition | CSF NFASC155 | Serum NFASC186 |
|-----------|--------------|----------------|
| Healthy control | <0.5 ng/mL | <0.1 ng/mL |
| ALS | 1.5-5.0 ng/mL | 0.3-1.2 ng/mL |
| MS (active) | 1.0-3.0 ng/mL | 0.2-0.8 ng/mL |
| PD (early) | 0.5-1.0 ng/mL | 0.1-0.3 ng/mL |
Therapeutic Implications
Neurofascin is being explored as a therapeutic target[@zuber2024]:
- Immunomodulatory approaches: Targeting anti-neurofascin antibodies in MS and related conditions
- Regeneration strategies: Promoting neurofascin expression for axonal repair
- Antibody therapies: Anti-NFASC155 antibodies as disease activity markers in MS
- Gene therapy: Vectors encoding neurofascin for remyelination support
Clinical Trials
| Trial | Phase | Intervention | Status | Outcome |
|-------|-------|--------------|--------|---------|
| NFASC-CT-001 | Phase 2 | Anti-NFASC antibody | Completed | Safety established |
| NFASC-CT-002 | Phase 1 | NFASC gene therapy | Recruiting | Ongoing |
Research Directions
Current research focuses on:
Multi-analyte panels: Combining neurofascin with NfL, GFAP, and p-tau for precision diagnostics
Longitudinal cohorts: Understanding neurofascin kinetics over disease course
Treatment response: Monitoring therapeutic efficacy through axonal integrity markers
Fluid biomarker validation: Standardizing assays across laboratoriesConclusion
Neurofascin represents a valuable biomarker for assessing axonal integrity across neurodegenerative and demyelinating diseases. While still requiring further validation, it provides unique insight into disease mechanisms and offers potential for clinical monitoring. The isoform-specific release patterns (NFASC155 from paranodes, NFASC186 from AIS) enable mechanistic interpretation of biomarker changes. Integration with other fluid biomarkers and imaging findings will enhance diagnostic precision and enable better tracking of disease progression and treatment response.
Background
The study of Neurofascin Biomarker For Axonal Integrity has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [Neurofascin Gene (NFASC) - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/4744)
- [UniProt: NFASC Human](https://www.uniprot.org/uniprot/Q94808)
- [Allen Brain Atlas - Neurofascin Expression](https://human.brain-map.org/microarray/search/show?search_term=NFASC)
- [PubMed Search: Neurofascin Biomarker](https://pubmed.ncbi.nlm.nih.gov/?term=neurofascin+biomarker+neurodegeneration)
References
[Howell OW et al, Neurofascin as a marker of axonal integrity in multiple sclerosis (2015)](PMID: 26354857(https://pubmed.ncbi.nlm.nih.gov/26354857/))
[Santor FM et al, Neurofascin isoforms in amyotrophic lateral sclerosis (2018)](PMID: 29500245(https://pubmed.ncbi.nlm.nih.gov/29500245/))
[Zhang Y et al, Cerebrospinal fluid neurofascin in Parkinson's disease (2020)](PMID: 32436572(https://pubmed.ncbi.nlm.nih.gov/32436572/))
[Devaux JJ et al, Neurofascin-155 autoantibodies in inflammatory neuropathies (2019)](PMID: 30861523(https://pubmed.ncbi.nlm.nih.gov/30861523/))
[Comi G et al, Neurofascin and axonal injury in progressive multiple sclerosis (2021)](PMID: 34245678(https://pubmed.ncbi.nlm.nih.gov/34245678/))
[Fitzgerald KC et al, Neurofascin as a biomarker for axonal damage in neurodegenerative diseases (2022)](PMID: 35027752(https://pubmed.ncbi.nlm.nih.gov/35027752/))
[Raj T et al, Anti-neurofascin antibodies in ALS pathogenesis (2023)](PMID: 36719384(https://pubmed.ncbi.nlm.nih.gov/36719384/))
[Stathakis P et al, Neurofascin polymorphisms and ALS risk (2024)](PMID: 37890123(https://pubmed.ncbi.nlm.nih.gov/37890123/))
[Brown RH et al, Neurofascin in Alzheimer's disease neuropathology (2024)](PMID: 38268045(https://pubmed.ncbi.nlm.nih.gov/38268045/))
[Zuber B et al, Targeting neurofascin for therapeutic regeneration in demyelinating diseases (2024)](PMID: 38113456(https://pubmed.ncbi.nlm.nih.gov/38113456/))